(4E,7E,10E,13E,16E)-二十二-4,7,10,13,16-戊烯酸 | 2313-14-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (4E,7E,10E,13E,16E)-二十二-4,7,10,13,16-戊烯酸
• 英文名称: docosapentaenoic acid
• 英文别名: 4,7,10,13,16-Docosapentaenoic acid；(4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoic acid
• CAS: 2313-14-6；25182-74-5
• 化学式: C₂₂H₃₄O₂
• 分子量: 330.511
• InChiKey: AVKOENOBFIYBSA-GUTOPQIJSA-N

物化性质

• 沸点：
  443.8±24.0 °C(Predicted)
• 密度：
  0.932±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

制备方法与用途

生物活性的 4,7,10,13,16-二十二碳五烯酸 (4,7,10,13,16-Docosapentaenoic Acid) 是一种内源性代谢产物。

文献信息

• BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
  申请人：Dietz Ulrich

  公开号：US20140099354A1

  公开（公告）日：2014-04-10

  The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.

  本发明涉及一种含硝基羧酸（s）的磷脂，用于涂覆医疗器械，如支架、导管球囊、伤口垫或外科缝合材料，以及用于生物钝化组合物，如漱口液、防水溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液，以及制备这些溶液和涂覆医疗器械以及它们的用途。
• [EN] SMALL MOLECULE COMPOUNDS TO SUPPORT HEALTHY HUMAN AGING<br/>[FR] COMPOSÉS À PETITES MOLÉCULES POUR FAVORISER UN VIEILLISSEMENT HUMAIN SAIN
  申请人：CARDAX PHARMA INC

  公开号：WO2018183353A1

  公开（公告）日：2018-10-04

  Disclosed herein are methods of activating expression of the FOXO3 gene in a subject comprising administering to a subject small molecule compound (such as astaxanthin and/or one or more astaxanthin derivatives), or pharmaceutically acceptable salts thereof, in an amount sufficient to at least partially increase the amount of FoxO3 expressed in the subject.

  本文揭示了一种激活主体中FOXO3基因表达的方法，包括向主体施用小分子化合物（如虾青素和/或一个或多个虾青素衍生物）或其药用可接受盐，以足够数量至少部分增加主体中表达的FoxO3的方法。
• Compositions comprising reverse isomers of conjugated linoleic acid
  申请人：Saebo Asgeir

  公开号：US20050215641A1

  公开（公告）日：2005-09-29

  The present invention relates to the field of human and animal nutrition, and in particular to certain novel compositions of conjugated linoleic acids (CLA). In particular, the present invention relates to CLA compositions comprising the c10,t12, c10,c12, t9,c11 and c9,c11 isomers of conjugated linoleic acid.

  本发明涉及人类和动物营养领域，特别是某些新颖的共轭亚油酸（CLA）组合物。具体而言，本发明涉及包含共轭亚油酸的c10,t12、c10,c12、t9,c11和c9,c11异构体的CLA组合物。
• 1-Phenylalkylpiperazines
  申请人：——

  公开号：US20040072839A1

  公开（公告）日：2004-04-15

  Described are novel 1-phenylalkylpiperazines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptor activity. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.

  描述了具有亲和力的新型1-苯基烷基哌嗪类化合物，这些化合物及其对映体、非对映异构体、N-哌嗪氧化物、多型体、溶剂合物和药学上可接受的盐在治疗下尿路神经肌肉功能障碍患者和与5-HT1A受体活性相关的疾病中具有用处。还描述了这些化合物的制备方法和含有它们的药物组合物。
• Phenylalkylamines and pyridylalkylamines
  申请人：——

  公开号：US20040058962A1

  公开（公告）日：2004-03-25

  Described are novel substituted phenylalkylamines and pyridylalkylamines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptor. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.

  描述了具有与5-羟色胺受体亲和力的新型取代苯基烷胺和吡啶基烷胺。这些化合物及其对映体、二对映体、N-氧化物、多晶型、溶剂合物和药用可接受的盐在治疗患有下尿路神经肌肉功能障碍和与5-HT1A受体相关疾病的患者中有用。还描述了这些化合物的制备以及含有它们的药物组合物。